文献速递肝病

在替诺福韦联合恩替卡韦治疗期间选择出高复制且部分多重耐药的rtS78T HBV聚合酶突变

Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy.
PubMed 文献 · J Hepatol · 2017-04-07

两例慢性HBV感染患者在接受恩替卡韦(ETV)与替诺福韦(TDF)双药抗病毒治疗期间病毒抑制不足,其中一例死于侵袭性肝细胞癌(HCC)。超深度焦磷酸测序发现两例均选择出rtS78T聚合酶突变,该突变同时于sC69产生提前终止密码子;体外功能分析显示rtS78T/sC69*突变显著增强病毒复制并降低对ETV和TDF的敏感性。

要点

  • 两例ETV+TDF双药治疗患者病毒抑制不足,均检出rtS78T/sC69*突变。
  • rtS78T/sC69*突变体外显著增强HBV复制并降低对ETV和TDF的敏感性。
  • sC69*导致HBs蛋白截短,损害商业HBsAg试剂检测,但不影响病毒分泌。

核心结论

  • rtS78T/sC69* HBV突变与复制增强及抗病毒治疗应答不足相关,可能有利于这些变异株长期持续存在。
  • 该突变在S蛋白抗原结构域缺失情况下仍持续分泌病毒颗粒并增加HBV转录本产生,可能使患者易感致癌效应。

研究设计与样本

  • 报告两例接受ETV与TDF双药抗病毒治疗但病毒抑制不足的HBV感染患者。
  • 对不同时间点血清样本进行超深度焦磷酸测序分析。
  • 将鉴定的HBV突变克隆至具有复制能力的HBV载体,体外转染肝癌细胞进行功能分析。
  • 评估复制效率、对抗病毒药物的耐药性及对HBV分泌(病毒颗粒、外泌体)的潜在影响。

主要发现

  • 测序分析显示两例均选择出rtS78T HBV聚合酶突变,该突变同时在sC69产生提前终止密码子,删除几乎整个小HBV表面蛋白。
  • 其中一例患者额外存在preS1/S2区域261bp缺失。
  • 体外功能分析显示rtS78T/sC69*突变而非preS1/S2缺失显著增强病毒复制,并降低对ETV和TDF的敏感性。
  • sC69*突变导致HBs蛋白截短,损害商业HBsAg试剂检测,但未引起细胞内HBsAg滞留或影响HBV分泌。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients chronically infected with the hepatitis B virus (HBV) and receiving long-term treatment with nucleoside or nucleotide analogues are at risk of selecting HBV strains with complex mutational patterns. We herein report two cases of HBV-infected patients with insufficient viral suppression, despite dual antiviral therapy with entecavir (ETV) and tenofovir (TDF). One patient died from aggressive hepatocellular carcinoma (HCC). METHODS: Serum samples from the two patients at different time points were analyzed using ultra-deep pyrosequencing analysis. HBV mutations were identified and transiently transfected into hepatoma cells in vitro using replication-competent HBV vectors, and functionally analyzed. We assessed replication efficacy, resistance to antivirals and potential impact on HBV secretion (viral particles, exosomes). RESULTS: Sequencing analyses revealed the selection of the rtS78T HBV polymerase mutation in both cases that simultaneously creates a premature stop codon at sC69 and thereby deletes almost the entire small HBV surface protein. One of the patients had an additional 261bp deletion in the preS1/S2 region. Functional analyses of the mutations in vitro revealed that the rtS78T/sC69∗ mutation, but not the preS1/S2 deletion, significantly enhanced viral replication and conferred reduced susceptibility to ETV and TDF. The sC69∗ mutation caused truncation of HBs protein, leading to impaired detection by commercial HBsAg assay, without causing intracellular HBsAg retention or affecting HBV secretion. CONCLUSIONS: The rtS78T/sC69∗ HBV mutation, associated with enhanced replication and insufficient response to antiviral treatment, may favor long-term persistence of these isolates. In addition to the increased production of HBV transcripts and the sustained secretion of viral particles in the absence of antigenic domains of S protein, this HBV mutation may predispose patients to carcinogenic effects. LAY SUMMARY: Long-term treatment with antiviral drugs carries the risk of selecting mutations in the hepatitis B virus (HBV). We herein report two cases of patients with insufficient response to dual tenofovir and entecavir therapy. Molecular analyses identified a distinct mutation, rtS78T/sC69∗, that abolishes HBsAg detection, enhances replication, sustains exosome-mediated virion secretion and decreases susceptibility to antivirals, thereby representing a potentially high-risk mutation for HBV-infected individuals.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Shirvani-Dastgerdi E, Winer BY, Celià-Terrassa T, et al. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. J Hepatol. 2017. PMID: 28392234. doi:10.1016/j.jhep.2017.03.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。